Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 349

The DOI matches its Crossref record; 20 of the 20 references it cites were found in a registry or an index.

Naturally occurring dominant resistance mutations to hepatitis C virus protease and polymerase inhibitors in treatment-naïve patients

Open access
Kuntzen, Thomas, Timm, Joerg, Berical, Andrew, Lennon, Niall, Berlin, Aaron M., Young, Sarah K., Lee, Bongshin, Heckerman, David, Carlson, Jonathan, Reyor, Laura L., Kleyman, Marianna, McMahon, Cory M., Birch, Christopher, Schulze zur Wiesch, Julian, Ledlie, Timothy, Koehrsen, Michael, Kodira, Chinnappa, Roberts, Andrew D., Lauer, Georg M., Rosen, Hugo R., Bihl, Florian, Cerny, Andreas, Spengler, Ulrich, Liu, Zhimin, Kim, Arthur Y., Xing, Yanming, Schneidewind, Arne, Madey, Margaret A., Fleckenstein, Jaquelyn F., Park, Vicki M., Galagan, James E., Nusbaum, Chad, Walker, Bruce D., Lake-Bakaar, Gerond V., Daar, Eric S., Jacobson, Ira M., Gomperts, Edward D., Edlin, Brian R., Donfield, Sharyne M., Chung, Raymond T., Talal, Andrew H., Marion, Tony, Birren, Bruce W., Henn, Matthew R., Allen, Todd M.·2008·Hepatology

Abstract

Resistance mutations to hepatitis C virus (HCV) nonstructural protein 3 (NS3) protease inhibitors in <1% of the viral quasispecies may still allow >1000-fold viral load reductions upon treatment, consistent with their reported reduced replicative fitness in vitro . Recently, however, an R155K protease mutation was reported as the dominant quasispecies in a treatment-naïve individual, raising concerns about possible full drug resistance. To investigate the prevalence of dominant resistance mutations against specifically targeted antiviral therapy for HCV (STAT-C) in the population, we analyzed HCV genome sequences from 507 treatment-naïve patients infected with HCV genotype 1 from the United States, Germany, and Switzerland. Phylogenetic sequence analysis and viral load data were used to identify the possible spread of replication-competent, drug-resistant viral strains in the population and to infer the consequences of these mutations upon viral replication in vivo . Mutations described to confer resistance to the protease inhibitors Telaprevir, BILN2061, ITMN-191, SCH6 and Boceprevir; the NS5B polymerase inhibitor AG-021541; and to the NS4A antagonist ACH-806 were observed mostly as sporadic, unrelated cases, at frequencies between 0.3% and 2.8% in the population, including two patients with possible multidrug resistance. Collectively, however, 8.6% of the patients infected with genotype 1a and 1.4% of those infected with genotype 1b carried at least one dominant resistance mutation. Viral loads were high in the majority of these patients, suggesting that drug-resistant viral strains might achieve replication levels comparable to nonresistant viruses in vivo . Conclusion: Naturally occurring dominant STAT-C resistance mutations are common in treatment-naïve patients infected with HCV genotype 1. Their influence on treatment outcome should further be characterized to evaluate possible benefits of drug resistance testing for individual tailoring of drug combinations when treatment options are limited due to previous nonresponse to peginterferon and ribavirin. (Hepatology 2008;48:1769–1778.)

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1002/hep.22549

Cites

20 of 20 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 20 references

Cited by

See all 349

Metadata

Authors
Kuntzen, T., Timm, J., Berical, A., Lennon, N., Berlin, A. M., Young, S. K., Lee, B., Heckerman, D., Carlson, J., Reyor, L. L., Kleyman, M., McMahon, C. M., Birch, C., Schulze zur Wiesch, J., Ledlie, T., Koehrsen, M., Kodira, C., Roberts, A. D., Lauer, G. M., Rosen, H. R., Bihl, F., Cerny, A., Spengler, U., Liu, Z., Kim, A. Y., Xing, Y., Schneidewind, A., Madey, M. A., Fleckenstein, J. F., Park, V. M., Galagan, J. E., Nusbaum, C., Walker, B. D., Lake-Bakaar, G. V., Daar, E. S., Jacobson, I. M., Gomperts, E. D., Edlin, B. R., Donfield, S. M., Chung, R. T., Talal, A. H., Marion, T., Birren, B. W., Henn, M. R., & Allen, T. M.
Venue
Hepatology
Published
2008-12
Volume
48
Issue
6
Pages
1769-1778
ISSN
0270-9139 (ISSN-L)
OpenAlex
W2019523835
Cited by
349
References
20
FWCI
26.25
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Naturally occurring dominant resistance mutations to hepatitis C virus protease and polymerase inhibitors in treatment-naïve patients. https://app.cochat.ai/papers/10.1002/hep.22549
The paper
Kuntzen, T., Timm, J., Berical, A., Lennon, N., Berlin, A. M., Young, S. K., Lee, B., Heckerman, D., Carlson, J., Reyor, L. L., Kleyman, M., McMahon, C. M., Birch, C., Schulze zur Wiesch, J., Ledlie, T., Koehrsen, M., Kodira, C., Roberts, A. D., Lauer, G. M., . . . Allen, T. M. (2008). Naturally occurring dominant resistance mutations to hepatitis C virus protease and polymerase inhibitors in treatment-naïve patients. Hepatology. https://doi.org/10.1002/hep.22549

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.